Cover Story
Regulatory News
In a unanimous vote, the FDA Oncologic Drugs Advisory Committee advised the agency to accept the metric of “minimal residual disease,” or MRD, as a basis for accelerated approvals of therapies in all settings of multiple myeloma.
In Brief
Clinical Roundup
Drugs & Targets
Trending Stories
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- Over three years as CEO, Karen Knudsen led ACS through COVID—and reversed the charity’s long slump
- Single-cell based precision oncology: First steps in addressing and overcoming tumor heterogeneity
- 2024 Karnofsky Award winner Lillian Siu talks about her career in phase I studies, ctDNA, and her mentor’s “evil red pencil”
- Biotech companies, investors pour billions into mRNA vaccines as research ramps up in cancer and non-communicable diseases